Cargando…

Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France

The emergence of SARS-CoV-2 variants calls for continuous monitoring of vaccine effectiveness (VE). We estimated the absolute effectiveness of complete 2-dose primary vaccination and booster vaccination with COVID-19 mRNA vaccines, and the duration of protection against Delta and Omicron BA.1 sympto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tamandjou Tchuem, Cynthia Raissa, Auvigne, Vincent, Vaux, Sophie, Montagnat, Charline, Paireau, Juliette, Monnier Besnard, Stéphanie, Gabet, Amélie, Benhajkassen, Nabil, Le Strat, Yann, Parent Du Chatelet, Isabelle, Levy-Bruhl, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968619/ https://www.ncbi.nlm.nih.gov/pubmed/36870880 http://dx.doi.org/10.1016/j.vaccine.2023.02.062

Ejemplares similares

Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021–January 2022: A retrospective, population-based, matched cohort study
por: Auvigne, Vincent, et al.
Publicado: (2022)

Effectiveness of second booster compared to first booster and protection conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France
por: Tamandjou, Cynthia, et al.
Publicado: (2023)

Impact of vaccination against severe COVID-19 in the French population aged 50 years and above: a retrospective population-based study
por: Tan-Lhernould, Laetitia, et al.
Publicado: (2023)

The use of reimbursement data for timely monitoring of vaccination coverage: the example of human papillomavirus vaccine following public concerns about vaccine safety
por: Fonteneau, Laure, et al.
Publicado: (2015)

Complications périnatales après une infection au SARS-CoV-2 selon le statut vaccinal à l'accouchement et les périodes de prédominance des variants : analyse des données nationales hospitalières françaises
por: Cahour, L., et al.
Publicado: (2023)

Complications périnatales après une infection au SARS-COV-2 selon le statut vaccinal à l’accouchement et les périodes de prédominance des variants : analyse des données nationales hospitalières françaises (mars 2020–mars 2022)
por: Cahour, L., et al.
Publicado: (2023)

Cost‐effectiveness of intensive care for hospitalized COVID-19 patients: experience from South Africa
por: Cleary, S. M., et al.
Publicado: (2021)

Impact of booster vaccination on the control of COVID-19 Delta wave in the context of waning immunity: application to France in the winter 2021/22
por: Bosetti, Paolo, et al.
Publicado: (2022)

A modelling study investigating short and medium-term challenges for COVID-19 vaccination: From prioritisation to the relaxation of measures
por: Tran Kiem, Cécile, et al.
Publicado: (2021)

Influenza vaccination coverage against seasonal and pandemic influenza and their determinants in France: a cross-sectional survey
por: Vaux, Sophie, et al.
Publicado: (2011)

Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021
por: Tran Kiem, Cécile, et al.
Publicado: (2021)

Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods
por: Link-Gelles, Ruth, et al.
Publicado: (2023)

Monitoring the reproductive number of COVID-19 in France: Comparative estimates from three datasets
por: Bonaldi, Christophe, et al.
Publicado: (2023)

Viral hepatitis associated hepatocellular carcinoma on the African continent, the past, present, and future: a systematic review
por: Dakurah, Ottovon Bismark, et al.
Publicado: (2021)

Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults
por: Kopel, Hagit, et al.
Publicado: (2023)

Monitoring the reproduction number of COVID-19 in France: estimates compared from 3 datasets: Christophe Bonaldi
por: Bonaldi, C, et al.
Publicado: (2022)

Is hepatitis B birth dose vaccine needed in Africa?
por: Tamandjou, Cynthia Raissa, et al.
Publicado: (2017)

Effectiveness of the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in England
por: Møller Kirsebom, Freja Cordelia, et al.
Publicado: (2022)

COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England
por: Kirsebom, Freja C M, et al.
Publicado: (2022)

Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodies
por: Carreño, Juan Manuel, et al.
Publicado: (2023)

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
por: Springer, David N., et al.
Publicado: (2023)

Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination
por: Habermann, Elisa, et al.
Publicado: (2022)

COVID-19 Pneumonia in Fully Vaccinated Adults during the Dominance of the Omicron Sublineages BA.1.1 and BA.2 in Mexico
por: Murillo-Zamora, Efrén, et al.
Publicado: (2022)

Chronic hepatitis B-associated liver disease in the context of human immunodeficiency virus co-infection and underlying metabolic syndrome
por: Amponsah-Dacosta, Edina, et al.
Publicado: (2020)

Estimated Effectiveness of Coadministration of the BNT162b2 BA.4/5 COVID-19 Vaccine With Influenza Vaccine
por: McGrath, Leah J., et al.
Publicado: (2023)

Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination
por: Lapointe, Hope R., et al.
Publicado: (2022)

Estimation of mRNA COVID-19 Vaccination Effectiveness in Tokyo for Omicron Variants BA.2 and BA.5: Effect of Social Behavior
por: Kodera, Sachiko, et al.
Publicado: (2022)

Mapping influenza activity in emergency departments in France using Bayesian model‐based geostatistics
por: Paireau, Juliette, et al.
Publicado: (2018)

Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections
por: Andeweg, Stijn P., et al.
Publicado: (2022)

Comparison of neutralization activity against Omicron BA.2/BA.5 in sera from HCWs receiving heterologous/homologous COVID-19 vaccines
por: Amano, Masayuki, et al.
Publicado: (2023)

Impact of non-pharmaceutical interventions, weather, vaccination, and variants on COVID-19 transmission across departments in France
por: Paireau, Juliette, et al.
Publicado: (2023)

Description des clusters de Covid-19 nosocomiaux chez des patients, France 2020-2022
por: Benhajkassen, N., et al.
Publicado: (2022)

Burden of influenza, healthcare seeking behaviour and hygiene measures during the A(H1N1)2009 pandemic in France: a population based study
por: Van Cauteren, Dieter, et al.
Publicado: (2012)

Assessment of the impact of the extension of vaccination mandates on vaccine coverage after 1 year, France, 2019
por: Lévy-Bruhl, Daniel, et al.
Publicado: (2019)

Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan
por: Arashiro, Takeshi, et al.
Publicado: (2023)

Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination
por: Assawakosri, Suvichada, et al.
Publicado: (2022)

COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022
por: Kliker, Limor, et al.
Publicado: (2022)

Association between vaccination status and severe health consequences among community-dwelling COVID-19 patients during Omicron BA.1/BA.2 and BA.5-predominant periods in Japan
por: Tomioka, Kimiko, et al.
Publicado: (2023)

Effectiveness of a Third Dose of COVID-19 mRNA Vaccine During the Omicron BA.1- and BA.2-Predominant Periods in Japan: The VENUS Study
por: Mimura, Wataru, et al.
Publicado: (2022)

Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort
por: Itamochi, Masae, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9svp60aql75ebbh6q3j84rdebj